Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 17;15(6):966.
doi: 10.3390/life15060966.

Seronegative Sicca Syndrome: Diagnostic Considerations and Management Strategies

Affiliations
Review

Seronegative Sicca Syndrome: Diagnostic Considerations and Management Strategies

Yordanka M Basheva-Kraeva et al. Life (Basel). .

Abstract

Seronegative sicca syndrome encompasses patients who present with xerostomia and/or keratoconjunctivitis sicca but lack anti-SSA/SSB antibodies and do not fulfill current classification criteria for primary Sjögren's syndrome (pSS). Despite symptom overlap with pSS, these individuals remain diagnostically and therapeutically unclassified. This review studies the clinical, immunological, and pathological spectrum of seronegative sicca, highlighting its heterogeneity and the limitations of antibody-centric diagnostic frameworks. Histopathologic findings in some seronegative patients-including focal lymphocytic sialadenitis-mirror those seen in pSS, suggesting underlying immune-mediated glandular damage. In others, nonspecific or normal biopsy findings suggest non-immune mechanisms. New evidence of immune activity, such as elevated cytokines (BAFF, IFN-α), and novel autoantibodies (SP-1, CA-VI), further supports the concept of subclinical autoimmunity in a subset of these patients. Clinically, they often face significant burden, including dryness, fatigue, and pain, yet remain excluded from most research cohorts, therapeutic trials, and clinical guidelines. Their management is often individualized, relying on symptomatic therapies rather than immunomodulatory agents. The lack of validated diagnostic criteria and prognostic markers compounds the uncertainty surrounding disease evolution, as some patients may later seroconvert or develop systemic features. To address these gaps, a paradigm shift is needed-one that embraces the spectrum of sicca syndromes, incorporates advanced immunophenotyping, and allows inclusion of seronegative patients in research and care algorithms.

Keywords: autoimmune exocrinopathy; primary Sjögren’s syndrome; seronegative sicca syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Proposed diagnostic framework for evaluating seronegative sicca syndrome. The chart guides clinicians from initial symptoms to biopsy findings and immunologic profiling.

Similar articles

Cited by

References

    1. Mariette X., Criswell L.A. Primary Sjögren’s syndrome. N. Engl. J. Med. 2018;378:931–939. doi: 10.1056/NEJMcp1702514. - DOI - PubMed
    1. Shiboski C.H., Shiboski S.C., Seror R., Criswell L.A., Labetoulle M., Lietman T.M., Rasmussen A., Scofield H., Vitali C., Bowman S.J., et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35–45. doi: 10.1002/art.39859. - DOI - PMC - PubMed
    1. Brito-Zeron P., Theander E., Baldini C., Seror R., Retamozo S., Quartuccio L., Bootsma H., Bowman S.J., Dörner T., Gottenberg J.-E., et al. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev. Clin. Immunol. 2016;12:137–156. doi: 10.1586/1744666X.2016.1109449. - DOI - PubMed
    1. Seror R., Mariette X., Bowman S., Baron G., Gottenberg J.E., Boostma H., Theander E., Tzioufas A., Vitali C., Ravaud P., et al. Accurate detection of changes in disease activity in primary Sjögren’s syndrome by ESSDAI. Arthritis Care Res. 2010;62:551–558. doi: 10.1002/acr.20173. - DOI - PubMed
    1. Quartuccio L., Baldini C., Bartoloni E., Priori R., Carubbi F., Corazza L., Alunno A., Colafrancesco S., Luciano N., Giacomelli R. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun. Rev. 2015;14:1019–1022. doi: 10.1016/j.autrev.2015.07.002. - DOI - PubMed

LinkOut - more resources